AFT gains Australian registration for intravenous Maxigesic

AFT gains Australian registration for intravenous Maxigesic
Jenny Ruth
By Jenny Ruth July 24 (BusinessDesk) - AFT Pharmaceuticals says it has successfully registered the intravenous form of its Maxigesic medication with Australia’s Therapeutic Goods Administration. The intravenous product contains 1,000 milligrams of paracetamol and 300mg of ibuprofen in a 100 millilitre solution. The company says it expects to sell the product in Australia during the year ending March 2020 and the registration “clears the way for regulatory filings in a number of other territories including but not limited to Mexico, Sou...

More Services

Sharesies founders sell down
Markets

Sharesies founders sell down

Global tech investor Rahul Mehta appears in Companies Office filings for the first time.

Pattrick Smellie 05 Nov 2025
Latest cap raise values Sharesies at $750m
Markets

Latest cap raise values Sharesies at $750m

In its eighth raise since 2017, Sharesies values its shares at $205 apiece.

Pattrick Smellie 10 Oct 2025
Two MC partners quit for specialist firm
Services

Two MC partners quit for specialist firm

Cuncannon now has a broader commercial offering. 

Staff reporters 06 Oct 2025
DB Breweries appoints new MD
Retail

DB Breweries appoints new MD

Peter Hart returns to NZ.

Victoria Young 01 Oct 2025